Allergan & Conde Nast International Announce International Content & Events Partnership for Beauty Decoded Live Series

Submitted by Forest Laboratories on Wed, 03/06/2019 - 22:10
Forest Laboratories's picture

Leading Global Medical Aesthetics Company Partners with Publisher of World’s Most Respected and Influential Media Titles in Fashion and Beauty --

-- Leading Global Medical Aesthetics Company Partners with Publisher of World’s Most Respected and Influential Media Titles in Fashion and Beauty --

-- Beauty Decoded Live Aims to Address Patient Barriers and Fears about Medical Aesthetics Treatment --

-- Partnership Includes Co-Branding for Events, Digital and Print Content Across Markets --

-- Partnership begins in the United Kingdom, and Reaches 10 Countries Across the World in 2019 --


London, United Kingdom – 7 March, 2019: Today Allergan, a world-leader in medical aesthetics, and Condé Nast International, publisher of many of the world’s most respected and influential media titles in beauty and fashion, announced an international content and events partnership for Beauty Decoded Live. Beauty Decoded Live is a series of global events designed to educate consumers on facial injectable fillers, dispel the myths of the modern aesthetic landscape and the importance of a proper consultation with a trained healthcare professional in the decision-making process, all to break down the barriers that cause consumer uncertainty with the category.

As part of the partnership, Condé Nast International and Allergan will hold co-branded events in several  countries. The events focus on education, and include presentations by a renowned panel of medical aesthetic experts, one-to-one consultations with leading practitioners and high-tech skin analysis. The fully immersive event aims to demystify the science of injectable fillers, explain the product options, provide guidance on the consultation and treatment process, and ultimately arm consumers with the knowledge they need. The campaign will be supported with amplification through print, digital and social content across Condé Nast International’s titles.

Marc Princen, Executive Vice President and President, International Business at Allergan said, “We are thrilled to partner with a world leading publisher like Condé Nast International, that reaches millions of beauty and fashion-conscious consumers, to be our media partner on the Beauty Decoded Live event series. As a medical aesthetics leader, Allergan has been training healthcare professionals on the use of our products for more than 15 years. This is the next step on that journey. It is the role a leader like Allergan must play to help patients address the questions they have about our products and medical aesthetics generally. By partnering with Condé Nast International, we can truly amplify our reach and impact as we roll out this series across global markets.”

Jamie Jouning, Chief Revenue Officer at Condé Nast International said “This collaboration presented a wonderful opportunity to showcase the ability of Condé Nast International to connect global brands with our sophisticated audiences across markets and cultures, through events and relevant content   activations. We are excited to cooperate with Allergan, a leader in the medical aesthetic sector and a business that lists innovation as one of its core values.

The global Beauty Decoded Live series kicks off on March 7, 2019, in London, UK and will reach 10 countries across the world in 2019, including Brazil, Italy, Spain, Australia, and Turkey.
 

About Beauty Decoded Live

With an ever-evolving medical aesthetics landscape, consumers have a growing desire to choose and control how they wish to look. At the same time, people remain unclear about the treatment journey and as a result, don’t have the confidence to take those initial first steps. The aim of Allergan’s Beauty Decoded Event, which is being rolled out globally, is to ‘decode’ medical aesthetics, so that consumers can seek reassurance and empowerment to book their first consultation.

With presentations by a renowned panel of medical aesthetic experts, one-to-one consultations with leading practitioners, high tech skin analysis, a live injection demonstration and plenty more, this fully immersive event aims to demystify the science of injectable fillers, explain the product options, provide guidance on the consultation and treatment process, and ultimately arm consumers with the knowledge they need to: Uncover it. Discover it. Decode it…and aim for the look they want.


About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
 
Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
 
For more information, visit Allergan’s website at www.Allergan.com.
 

About Condé Nast International

Condé Nast International (CNI) sets the benchmark for publishing excellence with leading print and digital brands including Vogue, Vanity Fair, GQ, Wired, and AD among others. Reaching more than 240 million consumers across Europe, the Middle East, Asia and Latin America, we are committed to delivering beautiful, influential content and brand experiences for individuals who demand to be inspired.
 
CNI is headquartered in London, and we operate in China, Japan, Taiwan, India, Russia, Italy, France, Spain, Germany, the UK and Mexico. In addition to publishing 30 brands, we run a licensing and restaurant division with local partners in 17 markets, the Condé Nast International Luxury Conference and several ventures in education. Committed to reinventing ourselves, we are constantly evaluating how we work across countries and brands and how we develop our products to expand our global leadership in the fashion, luxury and lifestyle spaces.
 
Please visit condenastinternational.com and follow Condé Nast International on LinkedIn or at @condenastint on .
 

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
 

 

Add new comment